Sign In
Buy RYTM
$84.71
+0.360 (+0.427%)
At Close: Jun 03, 2026
- European Commission decision anticipated in the second half of 2024 - BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutic
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
04:01pm, Tuesday, 11'th Jun 2024
BOSTON, June 11, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families liv
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
04:02pm, Monday, 03'rd Jun 2024
- Participants from the completed Phase 2 hypothalamic obesity trial reported positive changes in sleep, energy levels during setmelanotide therapy in qualitative interviews - - Separate analysis of p
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
08:02am, Monday, 03'rd Jun 2024
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families liv
IMCIVREE expected to be funded and available for use in England and Wales within three months through the National Health Service in specialist centres IMCIVREE expected to be funded and available for
Rhythm Pharmaceuticals, Inc (RYTM) Q1 2024 Earnings Call Transcript
09:50pm, Tuesday, 07'th May 2024
Rhythm Pharmaceuticals, Inc (NASDAQ:RYTM ) Q1 2024 Results Conference Call May 7, 2024 8:00 AM ET Company Participants David Connolly - Executive Director, IR and Corporate Communications David Meeker
The 3 Best Nasdaq Stocks to Buy in May 2024
02:52pm, Tuesday, 07'th May 2024
While conventional wisdom calls for selling securities, these best Nasdaq stocks may require a complete rethink. With the possibility that the Federal Reserve might get its soft landing after all, ris
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Misses Revenue Estimates
09:16am, Tuesday, 07'th May 2024
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $2.35 per share versus the Zacks Consensus Estimate of a loss of $2.34. This compares to loss of $0.92 per share a year ago.
Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
07:00am, Tuesday, 07'th May 2024
-- First quarter 2024 net revenue from global sales of IMCIVREE ® (setmelanotide) of $26.0 million -- -- On track to submit sNDA to the FDA to treat pediatric patients between 2 and younger than 6 ye
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Expected to Decline
11:06am, Tuesday, 30'th Apr 2024
Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Publication highlights administration of setmelanotide therapy resulted in a mean percent reduction in BMI of 15% at 16 weeks and 26% at one year of treatment -
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
04:01pm, Wednesday, 24'th Apr 2024
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families li
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
04:01pm, Tuesday, 16'th Apr 2024
BOSTON, April 16, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families li
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
08:00am, Monday, 01'st Apr 2024
-- Proceeds from financing and existing cash on-hand sufficient to fund planned operations into 2026 -- -- Proceeds from financing and existing cash on-hand sufficient to fund planned operations into
Hennion & Walsh's Kevin Mahn on his top stock picks: CRWD, MSFT, LLY, RYTM
09:33am, Thursday, 28'th Mar 2024
Kevin Mahn, Hennion & Walsh Asset Management president and CIO, joins 'Squawk Box' to discuss the latest market trends, why he believes AI isn't the only game in town for the markets, and more.
